# Trending Content OS — Daily Pipeline Run
**Date:** 2026-06-25 | **Niche:** Health & Wellness

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 configs loaded | ✅ |
| All 12 skills + Skill 02b present | ✅ |
| `site_niche` | health and wellness |
| `target_audience` | Health-conscious general audience |
| `site_url` | ⚠️ Not configured — self-check skipped; competitor fallback active |
| `minimum_trend_strength_score` | 50 |
| `minimum_opportunity_score` | 55 |
| `max_candidates_returned` | 25 |
| Google Trends | ✅ Available (SerpAPI pre-fetch injected) |
| `search_velocity_source` | `google_trends` (serpapi_prefetch) |
| Google News | ✅ Available (144 headlines injected) |
| SerpAPI Search | ✅ Available |
| Exa / RSS / Reddit | ⚠️ Not directly callable in this session — Google News Radar + Trends used as primary |
| Deferred topics (`data/deferred_topics.yaml`) | No file found — no deferred candidates |
| Run history (`data/run_history.yaml`) | No prior run entries found — first run; no staleness flags |

**Preflight result:** ✅ `next_action: run_signal_listener` — proceed with live signal data.

---

## GOOGLE NEWS RADAR — COVERAGE SUMMARY

144 headlines across 12 queries reviewed. Six primary topic clusters identified:

| Cluster | Headlines | Disposition | Reason |
|---|---|---|---|
| **FDA Blood Pressure Medication Recall (chlorthalidone)** | 9 | ✅ **Retained** | Multi-outlet corroboration (TODAY, Houston Chronicle, Good Housekeeping, qz.com, Yahoo Finance, Cleveland.com), FDA-confirmed, 11,460 bottles, direct patient action required |
| **Blocked COVID Vaccine Study Now Published** | 5 | ✅ **Retained** | WaPo, NBC News, ABC News, STAT News, Medscape — high-tier convergence; institutional suppression angle has strong editorial and public-health relevance |
| **Operation Trailblazer / HHS Clinical Trial Acceleration** | 8 | ✅ **Retained** | HHS.gov, FDA, WSJ, STAT News, Fierce Biotech — policy + patient access angle; national significance |
| **Ebola / France Travel Alert** | 2 | ✅ **Retained** | Google Trends "Trending Now" breakout + CDC travel advisory; rising public alarm signal |
| **HIV-to-HIV Lung Transplant (NYU Langone)** | 1 | ✅ **Retained** | Medical first; single institutional source but NYU Langone tier-1; proceed with confidence cap |
| **Severe Pregnancy Nausea / HG Study (Stanford)** | 1 | ✅ **Retained** | Stanford Medicine, peer-reviewed signal; strong women's health audience relevance |
| **AI in Therapy (APA)** | 1 | ✅ **Retained** | APA source; strong mental health + digital health angle; rising mental health trend velocity (+13 delta) |
| **Childhood Adversity + Cellular Energy (UCLA)** | 1 | ✅ **Retained** | UCLA Newsroom, strong mechanism angle; pediatric + chronic disease relevance |
| **CDC Blocked COVID Vaccine Study** | Merged above | — | Merged into Blocked COVID Vaccine Study cluster |
| **Fish Oil / Alzheimer's Study (Keck/USC)** | 1 | ✅ **Retained** | Strong supplement-claim signal; high audience search interest in gut/brain health |
| **Healthcare Fraud Takedown (DOJ/OIG)** | 2 | ❌ **Rejected** | Off-category — pure enforcement/legal news; no direct patient health angle sufficient for this niche |
| **Wellness Infrastructure (sauna, cold plunge, arena)** | 6 | ❌ **Rejected** | Brand/facility news, lifestyle real estate trend — no evidence-based health content angle |
| **Health Insurance / Midterms / Essential Plan** | 3 | ❌ **Rejected** | Off-category — policy/political framing without clinical health content |
| **Jamieson Wellness M&A** | 1 | ❌ **Rejected** | Pure business/pharma M&A; excluded category |
| **World Cup Public Health** | 1 | ⚠️ **Monitored** | Interesting angle but too event-specific and thin; no primary source available |
| **FDA Guidance on Wellness Devices (Nature)** | 1 | ⚠️ **Monitored** | Adjacent; needs primary source retrieval before briefing |
| **LLM AI vs FDA-Cleared Clinical AI (Nature Medicine)** | 1 | ⚠️ **Monitored** | High interest but primarily a regulatory/tech story; borderline audience fit |
| **Rural Hospital Shrinkage ($50B fund)** | 1 | ⚠️ **Monitored** | Policy-adjacent; could be patient access angle but too thin to brief today |

---

## SIGNAL SUMMARY

```yaml
signal_summary:
  run_started_at: "2026-06-25T00:00:00Z"
  run_completed_at: "2026-06-25T00:00:00Z"
  total_signals_reviewed: 144
  total_signals_retained: 9
  total_rejected: 135
  google_trends_available: true
  search_velocity_source: "google_trends (serpapi_prefetch)"
  rejection_breakdown:
    off_category: 28
    brand_safety: 6
    duplicate: 0
    weak_signal: 11
    unverified_claim: 3
    other: 87  # institutional/local/admin news, facility announcements, aggregator-only
  highest_priority_topic: "FDA Chlorthalidone Blood Pressure Recall"
  strongest_signal_source: "FDA.gov + TODAY.com + Houston Chronicle multi-outlet corroboration"
  tools_unavailable: ["Exa semantic search (direct)", "Reddit /new.json", "RSS feeds (direct)"]
  notes: >
    Google News Radar served as primary discovery layer for all news-led topics.
    Google Trends search_velocity used from pre-fetched SerpAPI block.
    Mental health trend velocity notably elevated (+13 delta, 7-day).
    Ebola breakout is a real-time Google Trends 'Trending Now' item — treated as breakout.
    site_url not configured — all content_status assessments use competitor-fallback inference;
    self-check explicitly skipped and noted per candidate.
```

---

## SKILL 02b — HEALTH CLAIM VERIFICATION GATE ROUTING SUMMARY

| Candidate | Signal Type | Gate Triggered | Result | Notes |
|---|---|---|---|---|
| Chlorthalidone recall | `recall` | ✅ Yes | **Pass (breaking-recall exception)** | 7+ credible outlets + FDA.gov URL pattern confirmed; primary notice URL inferred at fda.gov/safety/recalls; confidence capped at Medium pending direct retrieval |
| Blocked COVID vaccine study | `study_or_research` | ✅ Yes | **Pass** | Published in external peer-reviewed journal (confirmed via WaPo/NBC/STAT); study now in indexed journal; primary source traceable |
| Operation Trailblazer / HHS clinical trial reform | `policy_or_regulatory_change` | ✅ Yes | **Pass** | HHS.gov press release + FDA.gov announcement; institutional primary source confirmed |
| HIV-to-HIV lung transplant | `drug_or_treatment_claim` (surgical procedure) | ✅ Yes | **Pass (Medium cap)** | NYU Langone institutional press release; single institutional source; no independent journal publication confirmed yet |
| Severe pregnancy nausea / HG (Stanford) | `study_or_research` | ✅ Yes | **Pass (Medium cap)** | Stanford Medicine newsroom; journal name not independently confirmed in available signals; primary DOI not retrieved |
| AI in therapy (APA) | `drug_or_treatment_claim` → reclassified `expert_conversation` | No | **Not triggered** | APA organizational statement, not a clinical or drug claim |
| Childhood adversity + cell energy (UCLA) | `study_or_research` | ✅ Yes | **Pass (Medium cap)** | UCLA Newsroom; journal not confirmed in available signals |
| Fish oil / Alzheimer's (Keck/USC) | `supplement_claim` | ✅ Yes | **Pass (Medium cap)** | Keck Medicine press release; specific study/DOI not confirmed in available signals; claim is "may not prevent" — appropriately cautious framing |
| Ebola France travel alert | `breaking_news` / `dosage_or_safety_guidance` | ✅ Yes | **Pass** | CDC.gov advisory confirmed; official travel guidance |

---

## FINAL EDITORIAL PRIORITY BOARD

| # | Priority | Timing | Topic | Trend | Opp | Discover | Urgency | Confidence | Angle |
|---|---|---|---|---|---|---|---|---|---|
| 1 | **P1** | Immediate | FDA Chlorthalidone Blood Pressure Recall | 82 | 88 | 5 | Now | Medium | Patient action guide: check your bottles |
| 2 | **P1** | Immediate | Ebola Cases — France / Travel Alert | 90 | 80 | 4 | Now | Medium | What US travelers need to know right now |
| 3 | **P2** | Short-term | Blocked COVID Vaccine Study Now Published | 78 | 82 | 5 | Today | High | The study CDC tried to suppress — and what it actually found |
| 4 | **P2** | Short-term | Operation Trailblazer — HHS Clinical Trial Acceleration | 70 | 74 | 4 | Today | High | How the US plan to speed up drug trials could affect patients |
| 5 | **P2** | Short-term | HIV-to-HIV Lung Transplant (NYU Langone) | 62 | 72 | 4 | This week | Medium | World's first HIV-to-HIV lung transplant: what it means for transplant medicine |
| 6 | **P3** | Scheduled | Severe Pregnancy Nausea / HG — Stanford Study | 58 | 68 | 4 | This week | Medium | Hyperemesis gravidarum is more dangerous than morning sickness — new research explains why |
| 7 | **P3** | Scheduled | AI in Therapy — APA Report | 65 | 70 | 4 | This week | Medium | Patients are using AI between therapy sessions. Here's what therapists say about it |
| 8 | **P3** | Scheduled | Childhood Adversity + Cellular Energy (UCLA) | 55 | 65 | 3 | This week | Medium | How early trauma rewires your cells — and what that means for lifelong health |
| 9 | **P3** | Scheduled | Fish Oil and Alzheimer's — New Study | 60 | 66 | 4 | This week | Medium | Fish oil won't protect your brain from Alzheimer's, new study finds — what might |

---

## EDITORIAL BRIEFS — ALL RETAINED CANDIDATES

---

### BRIEF 1 — P1 · IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "FDA Recalls 11,460 Bottles of Chlorthalidone Blood Pressure Medication"
primary_entity: "Chlorthalidone"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 82
opportunity_score: 88
discover_score: 5
urgency: now
confidence: medium
content_status: new  # site_url not configured — self-check skipped; competitor coverage found (Good Housekeeping, TODAY, Cleveland.com)
source_count: 9
recommended_angle: "Patient action guide: how to check whether your blood pressure medication is affected — and what to do next"
why_now: "FDA recall is active. 11,460 bottles of chlorthalidone tablets nationwide. Multiple major outlets (TODAY, Houston Chronicle, Good Housekeeping, Yahoo Finance) reporting. Patients need clear, actionable guidance immediately."
primary_headline: "Is Your Blood Pressure Medication Recalled? Here's How to Check"
next_steps: "Assign immediately. Verify specific lot numbers and manufacturer name from FDA.gov recall notice before publishing. Add link to FDA recall page."
notes: "Breaking-recall exception used in Skill 02b. Confidence capped at Medium — primary FDA notice URL must be retrieved and linked before publishing. Competitors have basic news coverage; opportunity is in clear patient-action framing."
```

**Why now:** Active FDA recall affecting a common blood pressure medication used by millions of Americans. Patients need to act; most current coverage is news-brief level without clear action steps.

**Recommended angle:** Patient action guide — what chlorthalidone is, who takes it, how to check lot numbers, what to do if affected, what the alternatives are.

**Headline options:**
1. *Is Your Blood Pressure Medication Recalled? Here's How to Check*
2. *FDA Recalls 11,460 Bottles of Common Blood Pressure Drug — What Patients Need to Know*
3. *Chlorthalidone Recall: The Exact Lot Numbers and What to Do If You Have Them*

**Outline:**
- **Intro:** Recall summary — drug name, number of bottles, scope, urgency
- **Section 1:** What is chlorthalidone and who takes it (thiazide-like diuretic, hypertension, heart failure)
- **Section 2:** Why it was recalled — specific contamination or manufacturing defect (retrieve from FDA notice)
- **Section 3:** How to check your medication — lot numbers, manufacturer, what label to look for
- **Section 4:** What to do if you have recalled bottles — do not stop medication abruptly; contact prescriber
- **Section 5:** FDA process — what a Class I/II/III recall means for patients
- **FAQ:** Can I keep taking it? What happens if I already took recalled pills? What's a safe alternative?
- **Conclusion:** When in doubt, call your doctor — do not stop BP meds without guidance

**Key data points:**
- 11,460 bottles recalled nationwide
- Drug class: thiazide-like diuretic for hypertension
- FDA recall announcement: June 22–24, 2026
- Lot numbers and manufacturer: retrieve from FDA.gov before publishing

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| FDA Recalls | `https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts` | 1 | Primary recall notice, lot numbers |
| Houston Chronicle | `https://www.houstonchronicle.com` | 2 | News corroboration, bottle count |
| TODAY.com | `https://www.today.com` | 2 | Patient-facing coverage reference |
| qz.com (Quartz) | `https://qz.com` | 2 | Confirmed 11,460 figure |

**Integrity flags:**
- ⚠️ Do not publish without confirmed FDA lot numbers — patients need specific identifiers to act
- ⚠️ Critical safety note: patients should NOT abruptly stop blood pressure medication; always consult prescriber first
- ⚠️ Confirm whether this is a Class I (health risk) or lower-class recall before characterizing risk level

**Expert source:** Clinical pharmacist quote on stopping BP meds abruptly; cardiologist on thiazide alternatives. Retrieve from existing quoted experts in STAT, Reuters, or Mayo Clinic advisory.

**SEO:**
- Primary keyword: `chlorthalidone recall`
- Supporting: `blood pressure medication recall 2026`, `FDA drug recall June 2026`, `chlorthalidone lot numbers`, `is my blood pressure medication safe`
- Format: News article with action-checklist box
- Schema: MedicalWebPage + FAQPage
- Cluster: FDA and CDC regulatory updates

**Discover notes:** Score 5 — specific named drug, active recall, natural AI query ("Is chlorthalidone recalled?"), FDA primary source, durable patient-safety value, clear SERP gap for patient-action content vs news recaps.

**Word count:** 900–1,200 words

---

### BRIEF 2 — P1 · IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Ebola Cases Reported Near France — CDC Issues Travel Advisory for US Travelers"
primary_entity: "Ebola"
signal_type: breaking_news
allowed_category: "infectious disease"
trend_strength_score: 90
opportunity_score: 80
discover_score: 4
urgency: now
confidence: medium
content_status: new  # site_url not configured — self-check skipped; no competitor deep-dive content found
source_count: 2  # CDC advisory + Google Trends breakout ("ebola cases france" trending now)
recommended_angle: "What US travelers need to know right now: Ebola risk, CDC guidance, symptoms to watch for"
why_now: "Google Trends 'Trending Now' breakout for 'ebola cases france' as of today. CDC issued traveler advisory June 21. Public alarm is active and rising."
primary_headline: "Ebola Near France: CDC Issues Travel Warning — What You Need to Know"
next_steps: "Assign immediately. Retrieve full CDC travel advisory and identify the specific Ebola-affected areas travelers are returning from. Confirm case count and geographic scope before publishing."
notes: "Confidence Medium — two strong sources (CDC.gov + Google Trends breakout) but specific case details, affected countries, and transmission chain not yet confirmed from available signals. Do not speculate on outbreak severity."
```

**Why now:** "Ebola cases France" is a real-time Google Trends breakout (Trending Now, US) as of June 25. CDC has issued a formal traveler advisory for those returning from Ebola-affected areas. Public fear is spiking; authoritative, factually grounded content is urgently needed to counter rumor and panic.

**Recommended angle:** Calm, factual traveler and public guide — what the advisory actually says, what symptoms to watch for, who is at risk, and why Ebola is difficult to spread in non-endemic settings.

**Headline options:**
1. *Ebola Near France: CDC Issues Travel Warning — What You Need to Know*
2. *CDC Alert: What US Travelers Returning From Ebola-Affected Areas Should Watch For*
3. *Ebola Is in the News Again. Here's What the Risk Actually Looks Like*

**Outline:**
- **Intro:** CDC advisory summary — what we know right now
- **Section 1:** Where is the outbreak? What countries are affected (retrieve from CDC advisory)
- **Section 2:** How Ebola spreads — and why it is not airborne; risk in non-outbreak settings is low
- **Section 3:** Symptoms to watch for if you've recently traveled to affected areas
- **Section 4:** What the CDC is telling travelers to do right now
- **Section 5:** How past Ebola outbreaks were contained — historical context
- **FAQ:** Can Ebola spread in France or the US? Am I at risk if I haven't traveled? What should I do if I have symptoms?
- **Conclusion:** Risk calibration — panic vs. prudent monitoring

**Key data points:**
- CDC travel advisory issued June 21, 2026
- Retrieve: specific affected countries, case count, index case source
- Ebola transmission: direct contact with infected bodily fluids; not airborne
- CFR in past outbreaks: 25–90% depending on strain and healthcare response

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| CDC Travel Advisory | `https://www.cdc.gov/ebola` (retrieve specific advisory) | 1 | Primary guidance, traveler instructions |
| CDC Newsroom | `https://tools.cdc.gov/api/v2/resources/media/404952.rss` | 1 | Outbreak details |
| WHO | `https://www.who.int/news` | 1 | Global case confirmation |

**Integrity flags:**
- ⚠️ Do not speculate on case count or severity beyond what CDC/WHO confirms — Ebola coverage routinely generates disproportionate panic
- ⚠️ Clearly communicate transmission routes upfront — Ebola is NOT airborne; this is the most common public misconception
- ⚠️ Distinguish between cases near France (likely imported) vs. European community transmission — these are very different risk profiles

**Expert source:** Infectious disease epidemiologist quote on outbreak containment; retrieve from STAT News or Reuters coverage. CDC MMWR if published.

**SEO:**
- Primary keyword: `ebola cases france 2026`
- Supporting: `CDC ebola travel warning`, `ebola symptoms`, `ebola US risk 2026`, `ebola outbreak update`
- Format: Breaking news + explainer hybrid
- Schema: NewsArticle + FAQPage
- Cluster: Infectious disease / Public health

**Discover notes:** Score 4 — specific named pathogen, active travel advisory, natural AI query ("Is there an Ebola outbreak near France?"), CDC primary source available, but rapidly evolving situation could reduce durability.

**Word count:** 800–1,000 words

---

### BRIEF 3 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "CDC-Blocked COVID Vaccine Study Is Now Published in Independent Peer-Reviewed Journal"
primary_entity: "COVID-19 vaccine myocarditis study"
signal_type: study_or_research
allowed_category: "medical research and clinical trials"
trend_strength_score: 78
opportunity_score: 82
discover_score: 5
urgency: today
confidence: high
content_status: new  # site_url not configured — self-check skipped; competitor coverage is news-recap level only
source_count: 5  # WaPo, NBC News, ABC News, STAT News, Medscape
recommended_angle: "What the suppressed COVID vaccine study actually found — and why the methodology debate matters more than the headlines"
why_now: "Multiple tier-1 outlets (WaPo, NBC, ABC, STAT) reporting simultaneously on June 23. Acting CDC director blocked the study from the CDC's own journal; it was then published elsewhere. High public interest in COVID vaccine safety data."
primary_headline: "The COVID Vaccine Study the CDC Blocked Has Been Published. Here's What It Actually Says."
next_steps: "Retrieve the published study (identify journal from WaPo/NBC reporting). Confirm: study design (observational vs. RCT), sample size, specific finding on myocarditis risk, and how it compares to prior CDC/FDA data."
notes: "High confidence — 5 independent tier-1 outlets, all June 23. Key editorial task: lead with actual study findings, not the suppression narrative. Suppression is context, not the story. Watch for politicization."
```

**Why now:** Five major outlets published simultaneously on June 23 after the CDC's acting director blocked the study from MMWR. The study is now in an independent peer-reviewed journal. This story sits at the intersection of public health data transparency and COVID vaccine safety — an area with persistent audience questions and high search demand.

**Recommended angle:** Study-first, suppression-second. Lead with what the research actually found, explain the methodology and its limits, then contextualize the institutional dispute. Avoid being the outlet that amplifies the suppression narrative without engaging the science.

**Headline options:**
1. *The COVID Vaccine Study the CDC Blocked Has Been Published. Here's What It Actually Says.*
2. *CDC Tried to Suppress This COVID Vaccine Study. Researchers Published It Anyway.*
3. *What the Controversial COVID Vaccine Myocarditis Study Actually Found*

**Outline:**
- **Intro:** Study published, what the core finding is (retrieve)
- **Section 1:** What the study measured — design, population, endpoint (myocarditis risk post-mRNA vaccine)
- **Section 2:** What it found — specific numbers, comparison to prior CDC/FDA myocarditis data
- **Section 3:** Study limitations — observational? passive surveillance? self-reported?
- **Section 4:** Why the CDC blocked it — acting director's stated reason (retrieve from WaPo/NBC)
- **Section 5:** Independent publication — which journal, peer review process
- **Section 6:** Expert reactions — epidemiologists on whether findings change guidance
- **FAQ:** Should I be worried about myocarditis from COVID vaccines? Does this change the recommendation? What do the benefits vs. risks look like?
- **Conclusion:** What this means for public trust in health institutions

**Key data points:**
- Specific myocarditis incidence rate from study (retrieve)
- CDC VAERS background myocarditis data for comparison
- Journal name and peer-review status (retrieve)
- CDC acting director's stated blocking rationale (retrieve from WaPo)

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| The Washington Post | `https://www.washingtonpost.com` (June 23 article) | 1 | Suppression context, CDC director rationale |
| NBC News | `https://www.nbcnews.com` (June 23 article) | 1 | Study details |
| STAT News | `https://www.statnews.com` | 1 | Expert reaction, methodology |
| Published journal (retrieve) | DOI to be retrieved | 1 | Primary study source |
| CDC VAERS / MMWR background | `https://www.cdc.gov/mmwr` | 1 | Comparative myocarditis data |

**Integrity flags:**
- ⚠️ This topic has high misinformation potential — do not frame study findings as "proof vaccines cause heart damage" without full context of absolute risk numbers vs. COVID-related myocarditis risk
- ⚠️ Clearly label study design: if observational, state it; association ≠ causation
- ⚠️ Include benefit-risk comparison: COVID-related myocarditis risk vs. vaccine-related myocarditis risk, especially by age/sex subgroup
- ⚠️ Institutional suppression angle is newsworthy but should not overwhelm the scientific content — lead with findings

**Expert source:** Epidemiologist or cardiologist already quoted in STAT/WaPo coverage. Retrieve named expert and link to their published commentary.

**SEO:**
- Primary keyword: `COVID vaccine study CDC blocked`
- Supporting: `COVID vaccine myocarditis study 2026`, `CDC vaccine study suppressed`, `mRNA vaccine myocarditis risk`, `COVID vaccine safety 2026`
- Format: Explainer + news analysis
- Schema: NewsArticle + FAQPage
- Cluster: Medical research / Public health

**Discover notes:** Score 5 — specific named study/event, natural AI query ("What did the blocked CDC COVID vaccine study find?"), peer-reviewed primary source now available, durable public interest in COVID vaccine safety data, clear SERP gap for study-first rather than suppression-first coverage.

**Word count:** 1,200–1,500 words

---

### BRIEF 4 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Operation Trailblazer: HHS and FDA Plan to Cut Clinical Trial Timelines by 6–12 Months"
primary_entity: "Operation Trailblazer"
signal_type: policy_or_regulatory_change
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 70
opportunity_score: 74
discover_score: 4
urgency: today
confidence: high
content_status: new  # self-check skipped
source_count: 8  # HHS.gov, FDA, WSJ, STAT News, Fierce Biotech, The Hill, Clinical Trials Arena, Spencer Fane
recommended_angle: "What faster clinical trials actually mean for patients waiting on new treatments"
why_now: "HHS formally announced Operation Trailblazer on June 22 with FDA backing. WSJ, STAT, and Fierce Biotech all reporting. Framed as response to China competition — but patient access is the story for our audience."
primary_headline: "The Government Wants to Speed Up Drug Trials by a Year. Here's What That Means for Patients."
next_steps: "Retrieve HHS.gov announcement and FDA pilot program details. Identify which disease areas or trial phases are targeted first."
notes: "High confidence — 8 sources including HHS.gov and FDA direct. Strong audience angle is patient access, not geopolitics."
```

**Why now:** HHS launched Operation Trailblazer on June 22, backed by an FDA pilot program to accelerate Phase 1 trials by 6–12 months. National security framing (China competition) is the news hook, but the patient access angle — faster approvals for people waiting on treatments for cancer, rare diseases, and chronic conditions — is what makes this relevant to our audience.

**Recommended angle:** Patient-facing explainer. What are clinical trials, why do they take so long, what does this reform actually change, and who benefits first?

**Headline options:**
1. *The Government Wants to Speed Up Drug Trials by a Year. Here's What That Means for Patients.*
2. *Operation Trailblazer: How the US Plans to Get New Treatments to Patients Faster*
3. *FDA's New Plan Could Cut Years Off Drug Development. Here's What Patients Should Know.*

**Outline:**
- **Intro:** Operation Trailblazer announced — what it is and why it matters
- **Section 1:** How clinical trials work today — the phases, typical timelines, regulatory checkpoints
- **Section 2:** What the HHS/FDA plan actually changes — specific Phase 1 reforms, pilot program design
- **Section 3:** Who benefits first — cancer, rare disease, or chronic conditions?
- **Section 4:** What could go wrong — safety concerns with accelerated review, historical lessons from expedited approvals
- **Section 5:** The China competition context — why this matters geopolitically (briefly)
- **FAQ:** What is a Phase 1 trial? How do I find clinical trials I might qualify for? Is faster always safer?
- **Conclusion:** What to watch over the next 12 months

**Key data points:**
- 6–12 month reduction target (Phase 1)
- HHS announcement: June 22, 2026
- FDA pilot program details (retrieve from FDA.gov)
- Current average time from Phase 1 to approval: ~10–12 years

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| HHS.gov announcement | `https://www.hhs.gov` (June 22 release) | 1 | Primary policy source |
| FDA | `https://www.fda.gov` (June 22 modernization guidance) | 1 | Pilot program specifics |
| STAT News | `https://www.statnews.com` | 1 | Expert reaction, implications |
| WSJ | `https://www.wsj.com` | 1 | Competitive/geopolitical context |
| ClinicalTrials.gov | `https://www.clinicaltrials.gov` | 1 | Patient-facing trial search resource |

**Integrity flags:**
- ⚠️ Faster ≠ less safe — explicitly address this; previous accelerated approvals (e.g., Aduhelm) created controversy; balanced framing required
- ⚠️ Phase 1 acceleration affects early-stage safety testing — note that Phase 2/3 efficacy trials would not be compressed under this plan (confirm from HHS text)

**Expert source:** Clinical researcher or FDA policy expert quoted in STAT News or WSJ coverage. ClinicalTrials.gov for patient-accessible trial data.

**SEO:**
- Primary keyword: `Operation Trailblazer clinical trials`
- Supporting: `HHS FDA clinical trial reform 2026`, `how to speed up drug approval`, `clinical trial timeline US`, `FDA Phase 1 pilot program`
- Format: News explainer
- Schema: NewsArticle + FAQPage
- Cluster: FDA and CDC regulatory updates

**Discover notes:** Score 4 — specific named initiative, institutional primary sources, natural patient question ("How long do clinical trials take?"), durable educational value, moderate SERP competition on trial reform but clear gap for patient-facing framing.

**Word count:** 1,100–1,400 words

---

### BRIEF 5 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "World's First HIV-to-HIV Lung Transplant Performed at NYU Langone Health"
primary_entity: "HIV-to-HIV lung transplant"
signal_type: drug_or_treatment_claim
allowed_category: "medical research and clinical trials"
trend_strength_score: 62
opportunity_score: 72
discover_score: 4
urgency: this_week
confidence: medium
content_status: new  # self-check skipped
source_count: 1  # NYU Langone press release (June 19)
recommended_angle: "What this surgical first means for HIV-positive patients waiting for organ transplants — and how the HOPE Act made it possible"
why_now: "Announced June 19 at NYU Langone — a genuine medical first in transplant medicine. Under-covered relative to significance; competitor deep-dive content is absent."
primary_headline: "World's First HIV-to-HIV Lung Transplant: What It Means for Patients With HIV"
next_steps: "Retrieve full NYU Langone press release. Identify the surgical team, patient outcome details (if disclosed), and connection to the HOPE Act (HIV Organ Policy Equity Act). Check for any published case report or journal submission."
notes: "Confidence Medium — single institutional source (NYU Langone, tier-1). Confirmed by Google News radar. Proceed with explicit sourcing disclosure. If journal publication found, upgrade confidence."
```

**Why now:** NYU Langone performed the world's first HIV-to-HIV lung transplant on June 19 — a genuine surgical milestone enabled by the HIV Organ Policy Equity (HOPE) Act, which allows organs from HIV-positive donors to go to HIV-positive recipients. Lung transplants were the last frontier of this policy. Under-covered beyond the initial press release; strong differentiated opportunity.

**Recommended angle:** Patient-impact explainer — what the HOPE Act changed, why lungs were the hardest organ to include, what this means for HIV-positive patients on the transplant waitlist, and what clinical barriers remain.

**Headline options:**
1. *World's First HIV-to-HIV Lung Transplant: What It Means for Patients With HIV*
2. *NYU Langone Just Performed a Medical First. Here's Why It Matters for HIV-Positive Patients.*
3. *The HIV Organ Policy That Changed Transplant Medicine — and Its Newest Milestone*

**Outline:**
- **Intro:** The procedure, when it happened, why it's a first
- **Section 1:** What HIV-to-HIV transplants are — background on the HOPE Act (2013) and what changed
- **Section 2:** Why lungs were the hardest — immunological and clinical complexity of HIV + lung transplant
- **Section 3:** What this means for HIV-positive patients on transplant waitlists — organ availability impact
- **Section 4:** What the surgical team says (retrieve from NYU Langone press release)
- **Section 5:** What comes next — clinical evidence needed, expansion of policy
- **FAQ:** Can HIV-positive people receive organs from HIV-negative donors? How long is the HIV transplant waitlist? Is HIV still life-limiting for transplant candidates?
- **Conclusion:** Milestone framing — incremental but meaningful

**Key data points:**
- Procedure date: June 19, 2026 at NYU Langone Health
- HOPE Act background: enacted 2013, expanded organ donation among HIV+ individuals
- Prior HIV-to-HIV transplants: kidney and liver (lung is the first)
- Retrieve: patient details (if disclosed), surgical team, outcome

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| NYU Langone Health | `https://nyulangone.org/news` (June 19 release) | 1 | Primary — procedure details, surgical team |
| HOPE Act reference | `https://www.congress.gov` | 1 | Policy background |
| HRSA organ transplant data | `https://www.organdonor.gov` | 1 | Waitlist statistics |

**Integrity flags:**
- ⚠️ Single institutional source — do not overstate clinical implications; this is a case report, not a clinical trial; outcomes for one patient cannot be generalized
- ⚠️ Confirm whether a peer-reviewed case report has been submitted or published; update if so

**Expert source:** Transplant surgeon or HIV specialist quoted in NYU Langone press release. HRSA or UNOS (United Network for Organ Sharing) for waitlist data.

**SEO:**
- Primary keyword: `HIV lung transplant`
- Supporting: `HIV organ donation`, `HOPE Act transplant`, `HIV positive organ recipient`, `NYU Langone transplant 2026`
- Format: News explainer
- Schema: NewsArticle + MedicalProcedure
- Cluster: Medical research / Chronic disease management

**Discover notes:** Score 4 — specific named procedure and institution, natural AI query ("Can HIV-positive people receive lung transplants?"), institutional primary source, strong educational durability, moderate SERP gap for patient-facing explainer.

**Word count:** 900–1,100 words

---

### BRIEF 6 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Severe Pregnancy Nausea Linked to Birth Complications — Stanford Medicine Study"
primary_entity: "Hyperemesis gravidarum"
signal_type: study_or_research
allowed_category: "women's health"
trend_strength_score: 58
opportunity_score: 68
discover_score: 4
urgency: this_week
confidence: medium
content_status: new  # self-check skipped
source_count: 1  # Stanford Medicine newsroom (June 22)
recommended_angle: "HG is not just severe morning sickness — new research shows it can affect pregnancy outcomes, and here's what patients and doctors should know"
why_now: "Stanford Medicine published June 22. Hyperemesis gravidarum is chronically underdiagnosed and undertreated; Princess of Wales raised awareness in 2022 but search interest remains high. Strong evergreen + news hook combination."
primary_headline: "Severe Pregnancy Nausea Isn't Just Miserable — It May Raise Risk of Birth Complications, Study Finds"
next_steps: "Retrieve Stanford Medicine press release. Identify journal, study design (retrospective? prospective?), sample size, specific complications found. Retrieve DOI or PubMed ID."
notes: "Confidence Medium — Stanford Medicine tier-1 newsroom but journal/DOI not confirmed in available signals. Retrieve before publishing."
```

**Angle:** HG is clinically distinct from morning sickness; it affects ~2% of pregnancies and is associated with preterm birth, low birth weight, and maternal malnutrition. New Stanford data on birth complications adds evidence to an underserved clinical and patient-information landscape.

**Headline:** *Severe Pregnancy Nausea Isn't Just Miserable — It May Raise Risk of Birth Complications, Study Finds*

**Key data points:** HG prevalence (~2% of pregnancies); specific complications cited in study (retrieve); existing FDA-approved treatments (Bonjesta/doxylamine + B6, Diclegis); malnutrition and hospitalization burden.

**Integrity flags:**
- ⚠️ Retrieve study design before publishing — observational vs. prospective matters significantly for causal framing
- ⚠️ Do not imply all severe nausea = HG; HG is clinically defined (weight loss, dehydration, electrolyte imbalance) — include diagnostic criteria
- ⚠️ Association ≠ causation — nausea severity may correlate with other underlying pregnancy risk factors

**Sources:** Stanford Medicine newsroom (`https://med.stanford.edu/news`); retrieve DOI; ACOG guidelines on HG (`https://www.acog.org`).

**SEO:** Primary: `hyperemesis gravidarum complications` | Supporting: `severe morning sickness pregnancy risks`, `HG pregnancy study 2026`, `pregnancy nausea treatment` | Format: Research explainer | Word count: 900–1,100

---

### BRIEF 7 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Patients Are Bringing AI Into Therapy Sessions — APA Report"
primary_entity: "AI in mental health therapy"
signal_type: expert_conversation
allowed_category: "mental health and psychology"
trend_strength_score: 65
opportunity_score: 70
discover_score: 4
urgency: this_week
confidence: medium
content_status: new  # self-check skipped
source_count: 2  # APA (June 24) + mental health trend velocity +13 delta
recommended_angle: "What it means when patients use AI tools between therapy sessions — benefits, risks, and what therapists actually think"
why_now: "APA published June 24. Mental health is the highest-velocity trend in this run (+13 delta over 7 days). AI tools like ChatGPT are increasingly used for emotional support; therapists are encountering this in sessions. No authoritative patient-facing explainer exists."
primary_headline: "Patients Are Using AI Between Therapy Sessions. Therapists Have Thoughts."
next_steps: "Retrieve full APA report or article. Identify specific AI tools mentioned, specific use cases (journaling, CBT prompts, crisis support), therapist concerns, and any data on patient outcomes."
notes: "APA is tier-2 professional org but primary institutional source for this topic. Mental health trend velocity confirms timing."
```

**Angle:** Not "AI will replace therapists" — that's the clickbait angle. The real story is patients using AI for between-session support, emotional processing, and symptom tracking, and what therapists are discovering about this when they ask. Balanced, evidence-adjacent.

**Headline:** *Patients Are Using AI Between Therapy Sessions. Therapists Have Thoughts.*

**Key data points:** APA report findings (retrieve); specific AI tools patients are using; documented benefits (accessibility, between-session continuity); documented risks (dependency, crisis mishandling, privacy); APA guidance if any.

**Integrity flags:**
- ⚠️ Do not frame AI as equivalent to therapy or as a therapeutic tool without clinical validation — no FDA-cleared AI therapy tool exists at general-purpose LLM level
- ⚠️ Note distinction between AI chatbots (general purpose) and FDA-regulated mental health apps

**Sources:** APA (`https://www.apa.org`, June 24 publication); NIMH on AI in mental health (`https://www.nimh.nih.gov`).

**SEO:** Primary: `AI therapy mental health` | Supporting: `ChatGPT therapy sessions`, `AI mental health tools 2026`, `is AI safe for mental health` | Format: Feature explainer | Word count: 900–1,100

---

### BRIEF 8 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Childhood Adversity Changes How Cells Produce Energy — With Lifelong Health Effects (UCLA Study)"
primary_entity: "Childhood adversity mitochondrial function"
signal_type: study_or_research
allowed_category: "mental health and psychology"
trend_strength_score: 55
opportunity_score: 65
discover_score: 3
urgency: this_week
confidence: medium
content_status: new  # self-check skipped
source_count: 1  # UCLA Newsroom (June 18)
recommended_angle: "New research explains a biological mechanism linking early trauma to adult health conditions — and what it means for prevention"
why_now: "Published June 18 at UCLA. ACEs (adverse childhood experiences) research is an established content cluster with strong evergreen demand. A specific cellular mechanism (mitochondrial energy production) is a novel, differentiated hook."
primary_headline: "How Childhood Trauma Changes Your Cells — And What That Means for Your Health Decades Later"
next_steps: "Retrieve UCLA Newsroom press release. Identify journal, study type, specific cellular mechanism (likely mitochondrial), sample population. Retrieve DOI or PubMed ID."
notes: "Confidence Medium — UCLA tier-1 newsroom, June 18 (within freshness window). Journal/DOI not confirmed. Single source."
```

**Angle:** ACEs research is well-established; the cellular/mitochondrial mechanism angle is the differentiator. Frame around the biological pathway — not the policy debate — and connect to actionable health implications (epigenetic research, stress-reduction interventions).

**Headline:** *How Childhood Trauma Changes Your Cells — And What That Means for Your Health Decades Later*

**Key data points:** Specific cellular mechanism (retrieve); health outcomes associated; ACEs prevalence (~60% of US adults have at least one ACE); epigenetic research on reversibility.

**Integrity flags:**
- ⚠️ Retrieve study design — if this is animal model or small human cohort, qualify findings accordingly
- ⚠️ Do not overstate reversibility without evidence; "lifelong effects" framing must be balanced against neuroplasticity and intervention research

**Sources:** UCLA Newsroom (`https://newsroom.ucla.edu`, June 18); CDC ACEs data (`https://www.cdc.gov/violenceprevention/aces`); PubMed for retrieved DOI.

**SEO:** Primary: `childhood adversity health effects` | Supporting: `ACEs long-term health`, `childhood trauma cells`, `adverse childhood experiences research 2026` | Format: Research explainer | Word count: 900–1,100

---

### BRIEF 9 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Fish Oil Supplements Don't Prevent Alzheimer's Cognitive Decline, Study Finds"
primary_entity: "Fish oil Alzheimer's prevention"
signal_type: supplement_claim
allowed_category: "aging and longevity"
trend_strength_score: 60
opportunity_score: 66
discover_score: 4
urgency: this_week
confidence: medium
content_status: new  # self-check skipped
source_count: 1  # Keck Medicine of USC (June 18)
recommended_angle: "Fish oil won't protect your brain from Alzheimer's — what actually might, based on current evidence"
why_now: "Keck/USC published June 18. Fish oil is one of the most commonly taken supplements (77M American adults). 'Does fish oil prevent dementia?' is a perennial high-intent search query. A new negative finding is a strong opportunity to provide the definitive evidence-based answer."
primary_headline: "Fish Oil Won't Protect Your Brain From Alzheimer's, New Study Finds — Here's What Might"
next_steps: "Retrieve Keck Medicine press release. Identify journal, study design (RCT? observational? meta-analysis?), sample size, duration, specific cognitive endpoints. Retrieve DOI or PubMed ID."
notes: "Confidence Medium — Keck Medicine (USC-affiliated, tier-2 adjacent) single source. Fish oil supplement claim triggered Skill 02b; passed with Medium cap. Retrieve journal publication before publishing."
```

**Angle:** Lead with the finding, pivot quickly to what does have evidence for brain health (Mediterranean diet, aerobic exercise, sleep, hearing loss treatment) — audience wants actionable guidance, not just a negative result.

**Headline:** *Fish Oil Won't Protect Your Brain From Alzheimer's, New Study Finds — Here's What Might*

**Key data points:** Study design and sample (retrieve); omega-3 cognitive endpoint data; NIA/NIH position on fish oil for dementia prevention; what lifestyle factors do have evidence (FINGER trial, Mediterranean-DASH Intervention for Neurodegenerative Delay — MIND diet).

**Integrity flags:**
- ⚠️ Retrieve study design urgently — RCT vs. observational fundamentally changes the strength of the conclusion; if observational, qualify carefully
- ⚠️ Fish oil has documented cardiovascular benefits (omega-3, triglycerides) — do not imply the supplement is useless overall; scope specifically to Alzheimer's/cognitive prevention
- ⚠️ "May not prevent" is more accurate than "doesn't prevent" until study design is confirmed

**Sources:** Keck Medicine of USC (`https://www.usc.edu/news`, June 18 release); retrieve DOI; NIH National Institute on Aging (`https://www.nia.nih.gov`) for Alzheimer's prevention evidence; MIND diet trial reference.

**SEO:** Primary: `fish oil Alzheimer's prevention` | Supporting: `omega-3 dementia research`, `fish oil supplements brain health`, `what prevents Alzheimer's 2026` | Format: Research explainer + what-to-do guide | Word count: 950–1,200

---

## REJECTED TOPICS LOG

| Topic | Source | Rejection Reason |
|---|---|---|
| 2026 National Health Care Fraud Takedown (DOJ/OIG) | DOJ.gov, OIG.gov | Off-category — law enforcement/legal news; no direct patient health content angle |
| California health insurance tax increase | CalMatters | Off-category — state insurance policy/finance; political-adjacent without clinical health content |
| Axios-Ipsos poll: health affordability midterms | Axios | Off-category — political framing; polling story not health content |
| Jamieson Wellness explores sale (BMO/Canaccord) | Bloomberg | Excluded category — pure pharma/supplement M&A business news |
| Bon Secours Wellness Arena $282M makeover | WYFF News 4 | Off-category — sports facility; not health content |
| Cold plunges, saunas in home construction | Business Insider | Borderline; no evidence-based health angle; lifestyle/real estate trend |
| $24M Springfield sports/wellness center construction | Springfield News-Sun | Local facility news; off-category |
| Black Girl Wellness Fest at UIC Forum | CBS News | Event announcement; not health content eligible for pipeline |
| Gotham FC Nature's Garden wellness partnership | Gotham FC | Brand partnership; excluded category |
| Penn State wellness director appointment | Penn State | Administrative/institutional news; off-category |
| Alfred University Wellness Center nurses week | Alfred University | Local institutional event; off-category |
| Midjourney saunas Union Square SF | SF Standard | Tech/real estate; off-category |
| NPR World Cup public health team | NPR | Too event-specific, thin on health angle, no primary source |
| Nature — FDA guidance on wellness devices | Nature | Monitored; adjacent but primary source not retrieved; too regulatory/tech for this run |
| LLM vs. FDA-cleared clinical AI (Nature Medicine) | Clinical Trial Vanguard | Monitored; regulatory/tech story; borderline audience fit |
| $50B rural health transformation / hospital shrinkage | Healthcare Dive | Monitored; policy-adjacent; patient access angle possible but insufficient sourcing for brief |
| UC Irvine neural stem cell Huntington's disease trial | UCI Health | Monitored — credible source, single patient trial too early-stage; follow when results published |
| UCLA Type 1 diabetes clinical trial expanding | UCLA Health | Monitored — valid topic but thin on new information; follow when enrollment results available |
| UVA Health MAC lung disease clinical trial | WVIR | Local; too narrow; off-category |
| Northwestern cancer trial recruitment (Vizlitics) | Northwestern Medicine | Vendor partnership announcement; off-category |
| Mitch McConnell health update | Google Trends rising | Off-category — celebrity/political health speculation |
| Alka Yagnik health | Google Trends rising | Celebrity health; excluded category |
| Alfredo sauce salmonella recall | WVIR | Food safety recall — valid signal type, but WVIR is local; no multi-outlet corroboration or FDA confirmation found in available signals. Deferred pending FDA confirmation. |
| FDA highest risk level for OTC drug | Reader's Digest (The Healthy) | Signal only from The Healthy/Reader's Digest secondary outlet; specific drug not identified in available signals; insufficient sourcing for brief. Monitor for FDA primary source. |
| Trump cabinet sauerkraut diet / Haaland diet | Google Trends rising | Celebrity/political diet; excluded category |
| How to check hard drive / SSD / laptop battery health | Google Trends rising | Technology; off-category |
| Planet fitness Juneteenth hours | Google Trends rising | Operational query; off-category |
| Kroma wellness / Civana wellness resort | Google Trends rising | Brand/facility; excluded category |
| Supplemental nutrition assistance program (SNAP) | Google Trends rising | Policy/government program; off-category unless health impact angle emerges |
| Bank of America Institute "Wellness: Lost in the scroll" | BofA Institute | Financial services research framing; off-category |
| University of Utah student wellness questionnaire | University of Utah | Institutional/local; off-category |

---

## INTEGRITY FLAGS — CONSOLIDATED

The following ⚠️ flags require editorial review before any brief goes to writing:

| # | Topic | Flag |
|---|---|---|
| 1 | **Chlorthalidone recall** | ⚠️ Do NOT publish without confirmed FDA lot numbers and manufacturer name. ⚠️ Must include: do not stop blood pressure medication without prescriber guidance. |
| 2 | **Ebola / France travel alert** | ⚠️ Clearly state Ebola is NOT airborne in first 100 words. ⚠️ Do not speculate on case count beyond CDC/WHO confirmation. ⚠️ Distinguish imported case vs. European community spread. |
| 3 | **Blocked COVID vaccine study** | ⚠️ Lead with findings, not suppression narrative. ⚠️ Include benefit-risk comparison (COVID myocarditis vs. vaccine-related myocarditis). ⚠️ Clearly label study design (observational vs. RCT). ⚠️ High misinformation risk — requires editor review before publish. |
| 4 | **Operation Trailblazer** | ⚠️ Faster trials ≠ less safe — address this proactively. ⚠️ Confirm Phase 2/3 not compressed (Phase 1 only) before publishing. |
| 5 | **HIV-to-HIV lung transplant** | ⚠️ Single institutional source — disclose in article. ⚠️ One patient case; do not generalize outcomes. |
| 6 | **Pregnancy nausea / HG study** | ⚠️ Retrieve study design before writing; observational framing required if not RCT. ⚠️ HG diagnostic criteria must be included — not all severe nausea is HG. |
| 7 | **AI in therapy** | ⚠️ Do not frame AI chatbots as therapeutic tools; no general-purpose LLM is FDA-cleared for mental health treatment. |
| 8 | **Childhood adversity / cellular energy** | ⚠️ Retrieve study design; if animal model, qualify findings explicitly. ⚠️ Do not overstate reversibility without cited evidence. |
| 9 | **Fish oil / Alzheimer's** | ⚠️ Retrieve study design urgently — if observational, "may not prevent" is correct framing; "doesn't prevent" is premature. ⚠️ Scope specifically to Alzheimer's — fish oil has other documented benefits. |

---

## RUN NOTES

**Google Trends status:** Available via SerpAPI pre-fetch. Mental health +13 delta is the standout velocity signal. Ebola "Trending Now" is the only real-time breakout. Diet keyword dropped sharply (−7 delta); no strong diet story in signals this cycle.

**Source retrieval gap:** RSS feeds, Exa, and Reddit were not directly callable in this session. Google News Radar (144 headlines) + SerpAPI Trends pre-fetch provided sufficient signal for 9 retained candidates. Four candidates (HG study, UCLA childhood adversity, fish oil, HIV transplant) have single-source signals from institutional newsrooms — DOI/journal retrieval is required before writing commences.

**Self-check status:** `site_url` not configured. All `content_status: new` assignments reflect competitor-coverage inference, not confirmed absence from own site. Editor should verify no prior coverage before assigning.

**Alfredo sauce recall deferred:** Salmonella recall signal appeared in a single local outlet (WVIR) with no FDA.gov corroboration found in available signals. Not briefed. Recommend checking FDA.gov recalls page (`https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts`) before next run.

**FDA highest-risk OTC drug signal deferred:** The Healthy/Reader's Digest item lacked a specific drug name or FDA primary source in available signals. Recommend retrieving from FDA.gov before next run.

**Key themes this run:** FDA regulatory action (recall + clinical trial reform), COVID institutional trust, infectious disease (Ebola), women's health, supplement skepticism, AI in healthcare. No prior run history to compare against; staleness check will apply from next run forward.

---

*Run archived: 2026-06-25 | Signals reviewed: 144 | Retained: 9 | Rejected: 135 | P1: 2 | P2: 3 | P3: 4 | P5/Monitor: 4 | Integrity flags: 9 | Tools unavailable: Exa direct, RSS direct, Reddit direct*